OJR520 for Chronic Kidney Disease

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Recruiting Phase 1 Interventional Study
Chronic Kidney Disease
Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
112 (estimated)
Sponsor
Novartis Pharmaceuticals · Industry
Who this trial is looking for

This trial is looking for healthy adults and those with chronic kidney disease to help test a new drug called OJR520. Participants will receive the drug and be monitored for safety and how the body processes it.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 18 and 65 years old.
  • I can provide written informed consent.
  • I am in good health as checked by medical tests.

You may not be able to join if

  • I am a woman who can become pregnant.
  • I am a sexually active man and do not want to use contraception.
  • I have significant heart problems or serious medical conditions.
  • I have had a stroke or heart attack in the past.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Able to provide written informed consent before any assessment is performed. Part A (HV): • Healthy male and female participants in good health as determined by past medical history, physical examination, vital signs, 12-lead ECG, and laboratory tests at screening and baseline…
Contacts

Novartis Pharmaceuticals

1-888-669-6682

novartis.email@novartis.com

CONTACT

Novartis Pharmaceuticals

+41613241111

CONTACT